Lijst met verwijzingen naar andere richtlijnen
Uit Richtlijnen HIV
(Verschil tussen bewerkingen)
Regel 1: | Regel 1: | ||
+ | In onderstaande tabel staat de geschiedenis per pagina van deze richtlijn vermeld:<br> | ||
+ | |||
+ | {| width="100%" cellspacing="1" cellpadding="1" border="1" align="left" | ||
+ | |- | ||
+ | | valign="top" align="left" | '''Pagina'''<br> | ||
+ | | width="45" valign="top" align="left" | '''Datum eerste vaststelling'''<br> | ||
+ | | width="45" valign="top" align="left" | '''Datum ongewijzigde verlenging'''<br> | ||
+ | | width="45" valign="top" align="left" | '''Datum tekstuele aanpassing'''<br> | ||
+ | | width="45" valign="top" align="left" | '''Datum inhoudelijke aanpassing'''<br> | ||
+ | | valign="top" align="left" | '''Opmerkingen'''<br> | ||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Richtlijn HIV|Hoofdpagina (=inhoudsopgave)]]<br>''' | ||
+ | | width="45" valign="top" align="left" | 31-08-2010 | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | | ||
+ | | width="45" valign="top" align="left" | 26-05-2011* | ||
+ | | valign="top" align="left" | * Aanpassing titel hoofdstuk 16 | ||
+ | |- | ||
+ | | valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Hoofdstuk 1. Achtergrondinformatie bij de ontwikkeling en herziening van deze richtlijn en inleiding]]<br>''' | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | 26-05-2011<br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Procedure herziening]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | 26-05-2011<br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Samenstelling kernwerkgroep]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | 26-05-2011<br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Overzicht belangen werkgroepleden]] | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | 21-11-2011*<br> | ||
+ | | valign="top" align="left" | Update belangen werkgroepleden | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Definities]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | Geschiedenis per pagina van deze richtlijn (= huidige pagina)<br> | ||
+ | | width="45" valign="top" align="left" | 21-11-2011<br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Hoofdstuk 2. Therapie bij volwassenen]]<br>''' | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | 13-04-2011*<br> | ||
+ | | valign="top" align="left" | * Aanpassing titel 2.4<br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[2.1. Wanneer beginnen?]] <br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | 13-04-2011<br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Onderbouwing wanneer starten]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Literatuur 2.1]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[2.2. Keuze van antiretrovirale therapie bij naïeve volwassen patiënten]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | 13-04-2011<br> | ||
+ | | width="45" valign="top" align="left" | 16-09-2011*<br> | ||
+ | | valign="top" align="left" | * Aanpassing i.v.m. kostenoverweging<br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Literatuur 2.2]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[2.3. Tijdelijk onderbreken van HAART]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | 13-04-2011<br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[T½ van antiretrovirale middelen]] | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[2.4. Richtlijn anti-retrovirale therapie bij voorbehandelde patiënten]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | 13-04-2011<br> | ||
+ | | width="45" valign="top" align="left" | 13-04-2011*<br> | ||
+ | | valign="top" align="left" | * Aanpassing titel hoofdstuk<br> | ||
+ | |- | ||
+ | | valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Hoofdstuk 3. Behandeling van HIV-1 infectie bij kinderen]]<br>''' | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Hoofdstuk 4. Monitoring]]<br>''' | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[4.1. Controles HIV-patiënten (polikliniek)]] <br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Bij eerste consult bij HIV-seropositieve patiënt (polikliniek)]] | ||
+ | | width="45" valign="top" align="left" | 31-08-2010 | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | | ||
+ | | width="45" valign="top" align="left" | | ||
+ | | valign="top" align="left" | | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Bij instellen op antiretrovirale therapie (polikliniek)]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Eerste controle na instellen op anti-retrovirale therapie 4-6 weken na start (polikliniek)]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Controle van patiënten op antiretrovirale therapie (polikliniek)]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Controle van patiënten zonder antiretrovirale therapie (polikliniek)]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[4.2. Spiegelbepaling]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | 15-08-2011*<br> | ||
+ | | valign="top" align="left" | * Verwijzing naar nieuwe DHHS richtlijnen<br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[4.3. Resistentiebepalingen]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Hoofdstuk 5. Diagnostiek en behandeling primaire HIV-infectie]]<br>''' | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | 13-04-2011<br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Hoofdstuk 6. Therapietrouw bevorderende maatregelen]]<br>''' | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[6.1. Therapietrouw beïnvloedende factoren]] <br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Literatuur 6.1]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[6.2. Therapietrouw bevorderende interventies]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Onderbouwing therapietrouw bevorderende interventies]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Literatuur 6.2]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Hoofdstuk 7. Preventie van moeder-kind overdracht: zwangerschap, bevalling en neonatale periode]]<br>''' | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | 01-06-2011<br> | ||
+ | | width="45" valign="top" align="left" | 26-09-2011*<br> | ||
+ | | valign="top" align="left" | * Verwijzing nieuwe Amerikaanse richtlijn toegevoegd<br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Literatuur 7]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011<br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | 21-11-2011*<br> | ||
+ | | valign="top" align="left" | * Toevoeging dosering medicatie<br> | ||
+ | |- | ||
+ | | valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Hoofdstuk 8. HIV-2 bij volwassenen: Behandeling en monitoring]]<br>''' | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | 13-04-2011<br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Literatuur 8]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Hoofdstuk 9. Bijzondere omstandigheden]]<br>''' | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[9.1. Adviezen m.b.t. inname van anti-HIV middelen na braken]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[9.2. Adviezen m.b.t. inname van anti-HIV middelen bij vergeten van slikmoment]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[9.3. Marge tussen twee innames]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[9.4. Inname medicatie bij overschrijden tijdzones]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[9.5. Adviezen m.b.t. gebruik anti-HIV middelen door de sonde]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[9.6. Doseringen bij gestoorde lever- en nierfunctie]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Hoofdstuk 10. Behandeling van hepatitis B/C-virus coïnfectie bij HIV-1 positieve patiënten]]<br>''' | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[10.1. Hepatitis B]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | 21-11-2011*<br> | ||
+ | | valign="top" align="left" | * Verwijzing naar nieuwe richtlijn<br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[10.2. Hepatitis C (acuut)|10.2. Hepatitis C (acuut)]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 | ||
+ | | width="45" valign="top" align="left" | 21-11-2011<br> | ||
+ | | width="45" valign="top" align="left" | 26-05-2011*<br> | ||
+ | | valign="top" align="left" | * Verwijzing naar nieuwe literatuur<br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Levels of evidence]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Literatuur 10.2]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | 26-05-2011*<br> | ||
+ | | valign="top" align="left" | *Verwijzing naar nieuwe literatuur<br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[10.3. Hepatitis C (chronisch)|10.3. Hepatitis C (chronisch)]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011<br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | 21-11-2011*<br> | ||
+ | | valign="top" align="left" | * Link naar nieuwe richtlijn<br> | ||
+ | |- | ||
+ | | valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Hoofdstuk 11. Behandeling van tuberculose bij patiënten met een HIV-infectie]]<br>''' | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Literatuur 11]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Hoofdstuk 12. Comorbiditeit en bijwerkingen]]<br>''' | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 | ||
+ | | width="45" valign="top" align="left" | 26-05-2011<br> | ||
+ | | width="45" valign="top" align="left" | 21-11-2011*<br> | ||
+ | | valign="top" align="left" | * Verwijzing naar nieuwe richtlijn<br> | ||
+ | |- | ||
+ | | valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Hoofdstuk 13. Screening van HIV-patiënten op anogenitale maligniteiten]] <br>''' | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Onderbouwing screening van HIV-patiënten op anogenitale maligniteiten]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Literatuur 13]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Hoofdstuk 14. Interacties]]<br>''' | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Hoofdstuk 15. Profylaxe en behandeling van opportunistische infectie]]<br>''' | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 <br> | ||
+ | | width="45" valign="top" align="left" | 21-11-2011<br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | Hoofdstuk 16. Post Exposure Profylaxe na prikaccident en onveilig sexueel contact | ||
+ | | width="45" valign="top" align="left" | 31-08-2010 | ||
+ | | width="45" valign="top" align="left" | 14-12-2010<br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | 26-05-201* | ||
+ | | valign="top" align="left" | * Pagina opgeheven. Hiervoor in de plaats: <br> | ||
+ | [[Hoofdstuk 16. Transmissiereductie (PEP)]] | ||
+ | |||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Hoofdstuk 16. Transmissiereductie (PEP)]]<br>''' | ||
+ | | width="45" valign="top" align="left" | 26-05-2011<br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | 21-11-2011<br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[16.1. Prikaccidenten]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | 26-05-2011*<br> | ||
+ | | valign="top" align="left" | * Wijziging hoofdstuk, met verwijzing naar richtlijn LCI<br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[16.2. Seksaccidenten]]<br> | ||
+ | | width="45" valign="top" align="left" | 26-05-2011<br> | ||
+ | | width="45" valign="top" align="left" | 21-11-2011<br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Hoofdstuk 17. Vaccinatiebeleid]]<br>''' | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[17.1. Vaccinaties bij HIV-geïnfecteerde kinderen]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[17.2. Vaccinatie tegen influenza]] <br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Onderbouwing Vaccinatie tegen influenza]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Literatuur 17.2]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[17.3. Vaccinatie tegen infecties met Streptococcus pneumoniae (Pneumokokken)]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Onderbouwing Vaccinatie tegen infecties met Streptococcus pneumoniae (Pneumokokken) (Pneumokokken)]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Literatuur 17.3]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[17.4. Vaccinaties tegen Hepatitis A en B]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[17.5. Vaccinatie bij HIV-geïnfecteerde reizigers]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | [[Bureau's voor reizigersadvisering]]<br> | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | valign="top" align="left" | <br> | ||
+ | |- | ||
+ | | valign="top" align="left" | '''[[Hoofdstuk 18. Kostenoverzicht antiretrovirale middelen]]<br>''' | ||
+ | | width="45" valign="top" align="left" | 31-08-2010<br> | ||
+ | | width="45" valign="top" align="left" | 14-12-2010 26-05-2011 21-11-2011 | ||
+ | | width="45" valign="top" align="left" | <br> | ||
+ | | width="45" valign="top" align="left" | 16-09-2011*<br> | ||
+ | | valign="top" align="left" | * Opname tabel kosten HIV combinaties<br> | ||
+ | |} | ||
+ | |||
+ | <span style="background-color: rgb(255, 255, 0);">Vervallen?: | ||
+ | </span> | ||
+ | |||
+ | *[[Negatieve detuned ELISA|<span style="background-color: rgb(255, 255, 0);">Negatieve detuned ELISA</span>]] | ||
+ | *[[2.4. Richtlijnen bij salvage therapie|<span style="background-color: rgb(255, 255, 0);">2.4. Richtlijnen bij salvage therapie</span>]]<br> | ||
+ | |||
In onderstaande tabel staan verwijzingen naar andere richtlijnen opgesomd: | In onderstaande tabel staan verwijzingen naar andere richtlijnen opgesomd: | ||
<br> | <br> | ||
- | {| width="100%" cellspacing="0" cellpadding="0" border="1" style="mso-yfti-irow:0;mso-yfti-firstrow:yes | + | {| width="100%" cellspacing="0" cellpadding="0" border="1" class="MsoTableGrid" style="mso-yfti-irow:0;mso-yfti-firstrow:yes" |
|- | |- | ||
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | | | width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" | |
Versie op 9 dec 2011 14:24
In onderstaande tabel staat de geschiedenis per pagina van deze richtlijn vermeld:
Pagina | Datum eerste vaststelling | Datum ongewijzigde verlenging | Datum tekstuele aanpassing | Datum inhoudelijke aanpassing | Opmerkingen |
Hoofdpagina (=inhoudsopgave) | 31-08-2010 | 14-12-2010 21-11-2011 | 26-05-2011* | * Aanpassing titel hoofdstuk 16 | |
| | | | | |
Hoofdstuk 1. Achtergrondinformatie bij de ontwikkeling en herziening van deze richtlijn en inleiding | 31-08-2010 | 14-12-2010 21-11-2011 | 26-05-2011 | | |
Procedure herziening | 31-08-2010 | 14-12-2010 21-11-2011 | 26-05-2011 | | |
Samenstelling kernwerkgroep | 31-08-2010 | 14-12-2010 21-11-2011 | 26-05-2011 | | |
Overzicht belangen werkgroepleden | 31-08-2010 | 14-12-2010 26-05-2011 | | 21-11-2011* | Update belangen werkgroepleden |
Definities | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
Geschiedenis per pagina van deze richtlijn (= huidige pagina) | 21-11-2011 | | | | |
| | | | | |
Hoofdstuk 2. Therapie bij volwassenen | 31-08-2010 | 26-05-2011 21-11-2011 | | 13-04-2011* | * Aanpassing titel 2.4 |
2.1. Wanneer beginnen? | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | 13-04-2011 | | |
Onderbouwing wanneer starten | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
Literatuur 2.1 | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
2.2. Keuze van antiretrovirale therapie bij naïeve volwassen patiënten | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | 13-04-2011 | 16-09-2011* | * Aanpassing i.v.m. kostenoverweging |
Literatuur 2.2 | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
2.3. Tijdelijk onderbreken van HAART | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | 13-04-2011 | | |
T½ van antiretrovirale middelen | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
2.4. Richtlijn anti-retrovirale therapie bij voorbehandelde patiënten | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | 13-04-2011 | 13-04-2011* | * Aanpassing titel hoofdstuk |
| | | | | |
Hoofdstuk 3. Behandeling van HIV-1 infectie bij kinderen | 31-08-2010 | 14-12-2010 26-05-2011 | | | |
| | | | | |
Hoofdstuk 4. Monitoring | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
4.1. Controles HIV-patiënten (polikliniek) | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
Bij eerste consult bij HIV-seropositieve patiënt (polikliniek) | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | |||
Bij instellen op antiretrovirale therapie (polikliniek) | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
Eerste controle na instellen op anti-retrovirale therapie 4-6 weken na start (polikliniek) | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
Controle van patiënten op antiretrovirale therapie (polikliniek) | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
Controle van patiënten zonder antiretrovirale therapie (polikliniek) | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
4.2. Spiegelbepaling | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | 15-08-2011* | * Verwijzing naar nieuwe DHHS richtlijnen |
4.3. Resistentiebepalingen | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
| | | | | |
Hoofdstuk 5. Diagnostiek en behandeling primaire HIV-infectie | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | 13-04-2011 | | |
| | | | | |
Hoofdstuk 6. Therapietrouw bevorderende maatregelen | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
6.1. Therapietrouw beïnvloedende factoren | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
Literatuur 6.1 | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
6.2. Therapietrouw bevorderende interventies | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
Onderbouwing therapietrouw bevorderende interventies | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
Literatuur 6.2 | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
| | | | | |
Hoofdstuk 7. Preventie van moeder-kind overdracht: zwangerschap, bevalling en neonatale periode | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | 01-06-2011 | 26-09-2011* | * Verwijzing nieuwe Amerikaanse richtlijn toegevoegd |
Literatuur 7 | 31-08-2010 | 14-12-2010 26-05-2011 | | 21-11-2011* | * Toevoeging dosering medicatie |
| | | | | |
Hoofdstuk 8. HIV-2 bij volwassenen: Behandeling en monitoring | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | 13-04-2011 | | |
Literatuur 8 | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
| | | | | |
Hoofdstuk 9. Bijzondere omstandigheden | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
9.1. Adviezen m.b.t. inname van anti-HIV middelen na braken | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
9.2. Adviezen m.b.t. inname van anti-HIV middelen bij vergeten van slikmoment | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
9.3. Marge tussen twee innames | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
9.4. Inname medicatie bij overschrijden tijdzones | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
9.5. Adviezen m.b.t. gebruik anti-HIV middelen door de sonde | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
9.6. Doseringen bij gestoorde lever- en nierfunctie | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
| | | | | |
Hoofdstuk 10. Behandeling van hepatitis B/C-virus coïnfectie bij HIV-1 positieve patiënten | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
10.1. Hepatitis B | 31-08-2010 | 14-12-2010 26-05-2011 | | 21-11-2011* | * Verwijzing naar nieuwe richtlijn |
10.2. Hepatitis C (acuut) | 31-08-2010 | 14-12-2010 | 21-11-2011 | 26-05-2011* | * Verwijzing naar nieuwe literatuur |
Levels of evidence | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
Literatuur 10.2 | 31-08-2010 | 14-12-2010 21-11-2011 | | 26-05-2011* | *Verwijzing naar nieuwe literatuur |
10.3. Hepatitis C (chronisch) | 31-08-2010 | 14-12-2010 26-05-2011 | | 21-11-2011* | * Link naar nieuwe richtlijn |
| | | | | |
Hoofdstuk 11. Behandeling van tuberculose bij patiënten met een HIV-infectie | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
Literatuur 11 | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
| | | | | |
Hoofdstuk 12. Comorbiditeit en bijwerkingen | 31-08-2010 | 14-12-2010 | 26-05-2011 | 21-11-2011* | * Verwijzing naar nieuwe richtlijn |
| | | | | |
Hoofdstuk 13. Screening van HIV-patiënten op anogenitale maligniteiten | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
Onderbouwing screening van HIV-patiënten op anogenitale maligniteiten | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
Literatuur 13 | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
| | | | | |
Hoofdstuk 14. Interacties | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
| | | | | |
Hoofdstuk 15. Profylaxe en behandeling van opportunistische infectie | 31-08-2010 | 14-12-2010 26-05-2011 | 21-11-2011 | | |
| | | | | |
Hoofdstuk 16. Post Exposure Profylaxe na prikaccident en onveilig sexueel contact | 31-08-2010 | 14-12-2010 | | 26-05-201* | * Pagina opgeheven. Hiervoor in de plaats: |
Hoofdstuk 16. Transmissiereductie (PEP) | 26-05-2011 | | 21-11-2011 | | |
16.1. Prikaccidenten | 31-08-2010 | 14-12-2010 21-11-2011 | | 26-05-2011* | * Wijziging hoofdstuk, met verwijzing naar richtlijn LCI |
16.2. Seksaccidenten | 26-05-2011 | 21-11-2011 | | | |
| | | | | |
Hoofdstuk 17. Vaccinatiebeleid | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
17.1. Vaccinaties bij HIV-geïnfecteerde kinderen | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
17.2. Vaccinatie tegen influenza | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
Onderbouwing Vaccinatie tegen influenza | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
Literatuur 17.2 | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
17.3. Vaccinatie tegen infecties met Streptococcus pneumoniae (Pneumokokken) | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
Onderbouwing Vaccinatie tegen infecties met Streptococcus pneumoniae (Pneumokokken) (Pneumokokken) | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
Literatuur 17.3 | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
17.4. Vaccinaties tegen Hepatitis A en B | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
17.5. Vaccinatie bij HIV-geïnfecteerde reizigers | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
Bureau's voor reizigersadvisering | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | | |
| | | | | |
Hoofdstuk 18. Kostenoverzicht antiretrovirale middelen | 31-08-2010 | 14-12-2010 26-05-2011 21-11-2011 | | 16-09-2011* | * Opname tabel kosten HIV combinaties |
Vervallen?:
In onderstaande tabel staan verwijzingen naar andere richtlijnen opgesomd:
<o:p> </o:p> </div> </body></html>